New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 15, 2014
14:28 EDTCELGCelgene announces results from Phase III study of VIDAZA
Celgene International Sŕrl, a wholly-owned subsidiary of Celgene announced that results from AML-001, its phase III study of VIDAZA, azacitidine for injection, compared to conventional care regimens,CCR, in elderly subjects with newly-diagnosed acute myeloid leukemia were presented in a late-breaking abstract oral session at the 19th European Hematology Association annual congress. The study was presented by Pr. Hervé Dombret of the Hôpital Saint-Louis in Paris, France. In the global, multi-center, randomized, open-label pivotal study, patients at least 65 years old with newly diagnosed or secondary AML with > 30% bone marrow blasts were pre-selected to receive one of three regimens per investigator’s choice from intensive chemotherapy, low-dose Ara-C or best supportive care only. Patients then randomized to receive either azacitidine or their predetermined CCR . Median overall survival, OS, the primary endpoint of the study, was 10.4 months for patients receiving azacitidine compared to 6.5 months for patients receiving CCR, which did not achieve statistical significance.
News For CELG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 29, 2015
11:00 EDTCELGCelgene to hold an analyst and investor event
Subscribe for More Information
07:06 EDTCELGAmerican Society of Clinical Oncology to hold annual meeting
Subscribe for More Information
May 26, 2015
20:50 EDTCELGBernstein to hold a conference
Subscribe for More Information
07:39 EDTCELGCelgene management to meet with SunTrust
Group dinner to be held in New York on May 27 hosted by SunTrust.
May 21, 2015
08:08 EDTCELGAgios Pharmaceuticals to present data at 20th Congress of EHA
Subscribe for More Information
May 19, 2015
08:17 EDTCELGCelgene says patients experienced clinical remission in Phase II GED-0301 trial
Subscribe for More Information
May 18, 2015
08:44 EDTCELGCelgene data positive, says SunTrust
SunTrust believes that data presented for Celgene's GED-0301 in Crohn's indicated that the drug is effective irrespective of baseline disease severity and CRP levels.Consequently, the firm thinks the data addressed questions raised in an NEJM editorial about the drug. It keeps a $141 price target and Buy rating on the shares.
07:31 EDTCELGCelgene, Acceleron granted fast track designations for luspatercept
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use